Table 1.
Ref. | Year |
Patients (n) |
Follow-up period | Inclusion | Lymphadenectomy |
5-yr survival |
P value |
Recurrence |
|||
LG | OG | LG | OG | LG | OG | ||||||
Lee et al[18] | 2009 | 106 | 105 | 55.0 | cT1 | D2 | 95.9% | 94.9% | NS | 1 (0.94) | 1 (0.95) |
An et al[108] | 2010 | 42 | 162 | 35.0 | pT1N+ | D1 + β, D2 | 89.7% | 89.9% | NS | 4 (9.5) | 14 (8.6) |
Jeong et al[109] | 2011 | 138 | 261 | 36.8 | ≤ cT3N1 | D1 + β, D2 | Median OS: 30 mo | 35 (13.4) | 30 (21.7) | ||
MacLellan et al[110] | 2012 | 21 | 182 | 21.3 | Stage I-IV | - | 69.5% | 65.6% | NS | 8 (38.1) | 67 (36.8) |
(3YSR) | (3YSR) | ||||||||||
Hamabe et al[111] | 2012 | 66 | 101 | 30.4 (LG) | cT1 | D2 | 94.4% | 78.5% | NS | 4 (6.0) | 22 (21.7) |
53.3 (OG) | |||||||||||
Moisan et al[22] | 2012 | 31 | 31 | 50.0 | - | D1 + α, D1 + β, D2 | 74.0% | 75.0% | NS | 5 (16.1) | 4 (12.9) |
(3YSR) | (3YSR) | ||||||||||
Shinohara et al[46] | 2013 | 186 | 150 | 48.8 | cT2-4 | D2 | 68.1% | 63.7% | NS | 53 (28.4) | - |
Kim et al[42] | 2013 | 82 | 82 | 74.3 | ≤ cT1N1 | D2 | 97.6% | 96.3% | NS | 1 (1.2) | 2 (2.4) |
LG: Laparoscopic gastrectomy; OG: Open gastrectomy; OS: Overall survival.